Expand ZLAB Menu
ZLAB MENU

ZLAB Latest Press Releases

-- September 29, 2026 --

Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Business Wire 8:07 AM

-- August 17, 2026 --

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis Business Wire 6:00 AM

-- August 6, 2026 --

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates Business Wire 6:30 AM

-- August 3, 2026 --

U.S. FDA Grants Orphan Drug Designation to Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs) Business Wire 7:00 AM

-- July 22, 2026 --

Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026 Business Wire 7:30 AM

-- June 16, 2026 --

Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas Business Wire 7:00 AM

-- June 8, 2026 --

Zai Lab Receives China NMPA Approval of TIVDAK (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer Business Wire 8:34 PM

-- May 21, 2026 --

Zai Lab Announces Changes to Senior Leadership Team Business Wire 6:09 PM

-- May 11, 2026 --

Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs) Business Wire 7:00 AM

-- May 7, 2026 --

Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates Business Wire 6:00 AM
Market Data Delayed 15 Minutes